

## ASX Announcement

### Pharmaceutical Expert Joins Board of Directors

**SYDNEY, Australia, 24 April 2018:** Recce Pharmaceuticals Ltd (ASX: RCE) (**Recce** or the **Company**), developing a new class of synthetic antibiotics, today announced the appointment of Dr John Prendergast to its Board as an independent Non-Executive Director.

Dr Prendergast brings significant international experience in commercialising pharmaceuticals for global markets, most notably in the USA.

He is currently Chairman and Co-founder of Palatin Technologies, Inc. (NYSE: PTN), a US biotechnology company capitalised at over US\$260m, developing therapeutics for diseases with significant unmet medical need; Lead Director of Heat Biologics, Inc. (NASDAQ: HTBX) and Co-founder/Executive Chairman of Nejo, Inc.

Dr Prendergast said, "I am pleased to join Recce's Board at a pivotal time in the Company's development, as its new class of antibiotics continues to show significant promise in tackling the global health problem of superbugs. I look forward to supporting the Company's development program."

Executive Chairman Dr Graham Melrose said, "We welcome Dr Prendergast to the Board at a key point in our regulatory and commercial development. His experience in the US market will be invaluable as we progress our lead compound towards clinical trials in the USA."

#### **Additional professional background for Dr Prendergast**

Dr Prendergast has further held previous US biotechnology Board positions, most notably Lead Director of MediciNova, Inc. valued at over US\$470m (Nasdaq:MNOV) and Osaka Securities Exchange (#4875) and Co-founder/Lead Director of Avigen, Inc. which was acquired by MediciNova in 2009 for US\$37m. Prior to a career in commercialising pharmaceutical technologies, Dr Prendergast was Managing Director of Paramount Capital Investments and The Castle Group. Dr



ASX: RCE

**Head Office** Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

**R&D Centre - Perth** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

**Washington Office** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Prendergast has also served as a member of the Advisory Board for the Institute for the Biotechnology of Infectious Diseases (IBID) at the University of Technology Sydney, now called the ithree institute. An Australian citizen based in the USA, Dr Prendergast received his M.Sc. and Ph.D. degrees from the University of New South Wales, Sydney and a C.S.S. in Administration and Management from Harvard University. He has held Post-Doctoral Fellowships in the Department of Biochemistry and Molecular Biology, at Harvard University, and the Institute for Blood Diseases at L'Hospital St. Louis in Paris, France.

### **About Recce Pharmaceuticals Ltd**

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-man clinical trials.

---

For further information please visit [www.recce.com.au](http://www.recce.com.au) or contact:

#### **Investor Relations**

James Graham  
Executive Director  
Recce Pharmaceuticals Ltd  
Tel: +61 (02) 8075 4585

#### **Media (Australia)**

Andrew Geddes  
CityPR  
Tel: +61 (02) 9267 4511

#### **Media (International)**

Sue Charles/Gemma Harris  
Instinctif Partners  
Tel: +44 (0)20 7866 7860  
E: [recce@instinctif.com](mailto:recce@instinctif.com)

